Candel Therapeutics, Inc. — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Candel Therapeutics, Inc. appears in 7 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials7

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

7 shown

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094 · lead sponsor · 2026-06-15

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000 · lead sponsor · 2025-10-30

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153 · lead sponsor · 2020-10-13

ACTIVE_NOT_RECRUITING

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung CancerNCT03131037 · lead sponsor · 2017-05-04

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)NCT02768363 · lead sponsor · 2016-05-01

ACTIVE_NOT_RECRUITING

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionNCT01997190 · lead sponsor · 2013-10-01

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerNCT01436968 · lead sponsor · 2011-09-01

ACTIVE_NOT_RECRUITING

Sponsor roles

lead sponsor7

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.